Search results for "81.60"

showing 10 items of 308 documents

Evolutionary plasticity of SH3 domain binding by Nef proteins of the HIV-1/SIVcpz lentiviral lineage

2021

The accessory protein Nef of human and simian immunodeficiency viruses (HIV and SIV) is an important pathogenicity factor known to interact with cellular protein kinases and other signaling proteins. A canonical SH3 domain binding motif in Nef is required for most of these interactions. For example, HIV-1 Nef activates the tyrosine kinase Hck by tightly binding to its SH3 domain. An archetypal contact between a negatively charged SH3 residue and a highly conserved arginine in Nef (Arg77) plays a key role here. Combining structural analyses with functional assays, we here show that Nef proteins have also developed a distinct structural strategy—termed the "R-clamp”—that favors the formation …

RNA virusesviruksetvirusesSimian Acquired Immunodeficiency SyndromeHIV InfectionsPathology and Laboratory MedicineSH3 domainWhite Blood CellsImmunodeficiency VirusesAnimal CellsMedicine and Health SciencesBiology (General)MammalsGenetics11832 Microbiology and virology0303 health sciencesKinase030302 biochemistry & molecular biologyEukaryotavirus diseasesTransfection3. Good healthSIVMedical MicrobiologyViral PathogensViral evolutionVirusesVertebratesProto-Oncogene Proteins c-hckApesSimian Immunodeficiency VirusPathogensCellular TypesTyrosine kinaseResearch ArticlePrimateskinaasitEvolutionary ImmunologyLineage (genetic)QH301-705.5Immune CellsImmunologyevoluutioBiologyTransfectionResearch and Analysis MethodsHIV-tartuntaMicrobiologyViral EvolutionEvolution Molecularsrc Homology Domains03 medical and health sciencesVirologyRetrovirusesGeneticsAnimalsHumansLuciferaseAmino Acid Sequencenef Gene Products Human Immunodeficiency VirusChimpanzeesMolecular Biology TechniquesMicrobial PathogensMolecular Biology030304 developmental biologyEvolutionary BiologyBlood CellsSequence Homology Amino AcidMacrophagesLentivirusOrganismsBiology and Life SciencesHIVCell BiologyRC581-607Organismal Evolution3121 General medicine internal medicine and other clinical medicineMicrobial EvolutionAmniotesHIV-1ParasitologySalt bridgeproteiinitImmunologic diseases. AllergyZoology
researchProduct

Efeitos da sustentabilidade e valor logístico nas relações entre empresas de transporte marítimo

2020

Resumen El objetivo de este trabajo fue analizar cómo la sostenibilidad (económica, social y ambiental), bajo el enfoque de triple línea base, afecta la calidad de servicio, el valor logístico y la satisfacción en empresas del sector marítimo. Se propone un modelo teórico que se contrasta con la información suministrada por una muestra de 50 responsables de empresas (transitarios, importadores y exportadores) en Panamá. La información se analiza mediante la estimación de regresión por mínimos cuadrados parciales, que permite confirmar el carácter multidimensional de la sostenibilidad y del valor logístico. Los resultados también confirman que las percepciones de los clientes sobre las inici…

Responsabilidad social empresarialrelaciones business to businessEconomicsStrategy and Management//vocabularies.unesco.org/thesaurus/concept585 [http]Calidad de servicioRelaciones business to businessSatisfactionInternational tradeSocial responsibilityshipping industry//id.loc.gov/authorities/subjects/sh87004890 [http]Crecimiento económicoEmbarque de mercancíaspráticas sustentáveisCompañías de navegaciónindústria marítimaComercio internacionalManagement of Technology and InnovationShipment of goods//vocabularies.unesco.org/thesaurus/concept16052 [http]//vocabularies.unesco.org/thesaurus/concept3534 [http]logistic valueMarketing//id.loc.gov/authorities/subjects/sh85081260 [http]//id.loc.gov/authorities/subjects/sh85127728 [http]Responsabilidad socialCommerce internationalPrácticas sosteniblesMarine resources conservationSostenibilidadqualidade de serviçoQ56 SustainabilitySustainabilitybusiness-to-business relationships//vocabularies.unesco.org/thesaurus/concept6828 [http]Transporte marítimosustainable practicesEmploymentEconomics and Econometricsdemand supply and congestion [R41 Transportation]//id.loc.gov/authorities/subjects/sh85121576 [http]Steamboat linesConservación de los recursos marinos//id.loc.gov/authorities/subjects/sh85121579 [http]lcsh:Businessvalor logísticoindustria marítima//vocabularies.unesco.org/thesaurus/concept11744 [http]EconomíaShippingComercio exteriorSatisfacciónTransporte acuáticoBusiness and International Management//id.loc.gov/authorities/subjects/sh2009000375 [http]Economic growth//vocabularies.unesco.org/thesaurus/concept682 [http]calidad de servicioEconómicasprácticas sosteniblesIndustria marítimarelações business to businessSocial responsibility of business//id.loc.gov/authorities/subjects/sh85040850 [http]Maritime transport//id.loc.gov/authorities/subjects/sh85020473 [http]quality of service//id.loc.gov/authorities/subjects/sh85117681 [http]CarriersValor logísticolcsh:HF5001-6182Empresas de transporteEmpleoFinance
researchProduct

Rotavirus stimulates release of serotonin (5-HT) from human enterochromaffin cells and activates brain structures involved in nausea and vomiting

2011

Rotavirus (RV) is the major cause of severe gastroenteritis in young children. A virus-encoded enterotoxin, NSP4 is proposed to play a major role in causing RV diarrhoea but how RV can induce emesis, a hallmark of the illness, remains unresolved. In this study we have addressed the hypothesis that RV-induced secretion of serotonin (5-hydroxytryptamine, 5-HT) by enterochromaffin (EC) cells plays a key role in the emetic reflex during RV infection resulting in activation of vagal afferent nerves connected to nucleus of the solitary tract (NTS) and area postrema in the brain stem, structures associated with nausea and vomiting. Our experiments revealed that RV can infect and replicate in human…

RotavirusViral DiseasesViral Nonstructural ProteinsMiceChildlcsh:QH301-705.5Mice Inbred BALB CArea postremaBrainNauseaVagus NerveJejunumInfectious DiseasesMEDICINChild PreschoolEnterochromaffin cellVomitingMedicineSerotonin Antagonistsmedicine.symptomProto-Oncogene Proteins c-fosResearch Articlelcsh:Immunologic diseases. Allergymedicine.medical_specialtySerotoninVomitingImmunologyBiologyMicrobiologyRotavirus InfectionsSDG 3 - Good Health and Well-beingInternal medicineCell Line TumorVirologyGeneticsmedicineEnterochromaffin CellsAnimalsHumansBiologyMolecular BiologyGlycoproteinsToxins BiologicalMEDICINEVagus nerveEndocrinologyGene Expression Regulationlcsh:Biology (General)Cell cultureParasitologyEnteric nervous systemCalciumSerotoninlcsh:RC581-607Ex vivo
researchProduct

Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma

2019

AIMS: Mobile Airways Sentinel NetworK (MASK) belongs to the Fondation Partenariale MACVIA-LR of Montpellier, France and aims to provide an active and healthy life to rhinitis sufferers and to those with asthma multimorbidity across the life cycle, whatever their gender or socio-economic status, in order to reduce health and social inequities incurred by the disease and to improve the digital transformation of health and care. The ultimate goal is to change the management strategy in chronic diseases. METHODS: MASK implements ICT technologies for individualized and predictive medicine to develop novel care pathways by a multi-disciplinary group centred around the patients. STAKEHOLDERS: Incl…

SENTINEL NETWORKAllergyRespiratory Medicine and AllergyReviewWORLD-HEALTH-ORGANIZATIONDiseaseRhinitis.App; Asthma; Care pathways; DG Santé; MASK; mHealth; Rhinitis0302 clinical medicineQUALITY-OF-LIFEPRECISION MEDICINEDG SantéHealth careMedicine and Health SciencesGRADING QUALITYImmunology and AllergyMedicinemHealthRinitisLungmedicin och allergiRhinitis0303 health sciencesThe MASK study groupPublic sectorApp ; Asthma ; Care pathways ; MASK ; mHealth ; Rhinitis ; DG SanteMOBILE TECHNOLOGY3. Good healthALLERGIC RHINITISCHRONIC RESPIRATORY-DISEASESRinitemHealthCare pathwaysEUROPEAN SYMPOSIUMCLINICAL-PRACTICE GUIDELINESLife Sciences & BiomedicinePulmonary and Respiratory Medicinemedicine.medical_specialtyMASKImmunologySettore MED/10 - Malattie Dell'Apparato RespiratorioPredictive medicine03 medical and health sciencesQuality of life (healthcare)App -MASKAsma030304 developmental biologyAsthmaARIAScience & TechnologyCare pathwaybusiness.industryChange managementCorrectionDG SanteRC581-607medicine.diseaseAsthma030228 respiratory systemApp; Asthma; Care pathways; DG Santé; MASK; mHealth; Rhinitis; Immunology and Allergy; Immunology; Pulmonary and Respiratory MedicineFamily medicineImmunologic diseases. AllergybusinessApp[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

SPARC is a new myeloid-derived suppressor cell marker licensing suppressive activities

2019

Myeloid-derived suppressor cells (MDSC) are well-known key negative regulators of the immune response during tumor growth, however scattered is the knowledge of their capacity to influence and adapt to the different tumor microenvironments and of the markers that identify those capacities. Here we show that the secreted protein acidic and rich in cysteine (SPARC) identifies in both human and mouse MDSC with immune suppressive capacity and pro-tumoral activities including the induction of epithelial-to-mesenchymal transition (EMT) and angiogenesis. In mice the genetic deletion of SPARC reduced MDSC immune suppression and reverted EMT. Sparc−/− MDSC were less suppressive overall and the granu…

STAT3 Transcription Factorlcsh:Immunologic diseases. Allergy0301 basic medicineEpithelial-Mesenchymal TransitionAngiogenesisImmunologyneutrophil extracellular trapsNitric Oxide Synthase Type IIInflammationExtracellular TrapsMice03 medical and health sciences0302 clinical medicineImmune systemBreast cancermedicineMyeloid-derived suppressor cellAnimalsHumansImmunology and AllergyOsteonectinOriginal ResearchMice KnockoutMice Inbred BALB CTumor microenvironmentArginaseChemistryNeutrophilNF-kappa B p50 SubunitSPARCNeutrophil extracellular trapsmyeloid-derived suppressor cells030104 developmental biologyCancer researchMyeloid-derived Suppressor CellTumor necrosis factor alphaSignal transductionmedicine.symptomlcsh:RC581-607Neutrophil extracellular trapBiomarkers030215 immunology
researchProduct

Resveratrol-induced xenophagy promotes intracellular bacteria clearance in intestinal epithelial cells and macrophages

2019

International audience; Autophagy is a lysosomal degradation process that contributes to host immunity by eliminating invasive pathogens and the modulating inflammatory response. Several infectious and immune disorders are associated with autophagy defects, suggesting that stimulation of autophagy in these diseases should be bene ficial. Here, we show that resveratrol is able to boost xenophagy, a selective form of autophagy that target invasive bacteria. We demonstrated that resveratrol promotes in vitro autophagy-dependent clearance of intracellular bacteria in intestinal epithelial cells and macrophages. These results were validated in vivo using infection in a transgenic GFP-LC3 zebra f…

Salmonella typhimuriumrestrictionResveratrolresveratrolMicechemistry.chemical_compound0302 clinical medicine[SDV.IDA]Life Sciences [q-bio]/Food engineeringImmunologieXenophagyImmunology and AllergyIntestinal MucosaZebrafishOriginal Research0303 health sciencessalmonella infectionbiologyChemistrycrohns-disease[SDV.IDA] Life Sciences [q-bio]/Food engineering3. Good healthCell biologyrégime alimentaire030220 oncology & carcinogenesisHost-Pathogen InteractionsAIEClcsh:Immunologic diseases. AllergyautophagysalmonelleTransgenesalmonellaImmunologyautophagieCell Line03 medical and health sciencesImmune systemxenophagyEscherichia coliAnimalsHumans030304 developmental biologyselective autophagyhealthy-volunteersmodelEnterocolitisMacrophagesIntracellular parasiteAutophagylife-span extensionautophagy;resveratrol;xenophagy;salmonella;AIECagent resveratrolEpithelial Cellsbiology.organism_classification[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologyCell cultureactivation[SDV.MP.BAC] Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriologyproteinlcsh:RC581-607Bacteria
researchProduct

Salmonella bongori Provides Insights into the Evolution of the Salmonellae

2011

The genus Salmonella contains two species, S. bongori and S. enterica. Compared to the well-studied S. enterica there is a marked lack of information regarding the genetic makeup and diversity of S. bongori. S. bongori has been found predominantly associated with cold-blooded animals, but it can infect humans. To define the phylogeny of this species, and compare it to S. enterica, we have sequenced 28 isolates representing most of the known diversity of S. bongori. This cross-species analysis allowed us to confidently differentiate ancestral functions from those acquired following speciation, which include both metabolic and virulence-associated capacities. We show that, although S. bongori…

Salmonellamedicine.disease_causeSettore MED/42 - Igiene Generale E ApplicataTranslocation GeneticEnteropathogenic Escherichia coli1108 Medical MicrobiologySalmonellaCOMPLETE GENOME SEQUENCEIII SECRETION SYSTEMBiology (General)PATHOGENICITY ISLAND 2PhylogenyGenetics0303 health sciencesbiologyVirulenceEffectorPARASITOLOGYENTERICA SEROVAR TYPHIMURIUMSalmonella entericaGenomicsSalmonella bongori evolutionary genomicsBiological EvolutionUREIDOGLYCOLLATE LYASEInfectious DiseasesSalmonella enterica1107 ImmunologyQR180MedicineKLEBSIELLA-PNEUMONIAELife Sciences & BiomedicineResearch Article0605 MicrobiologySalmonella bongoriMICROBIOLOGYESCHERICHIA-COLI K-12Genomic IslandsQH301-705.5Sequence analysisVirulence FactorsImmunologyVirulenceVIROLOGYENCODED EFFECTORsalmonella; salmonella bongori; evoluzione geneticaMicrobiologyQH30103 medical and health sciencesVirologyGeneticsmedicineMICROARRAY ANALYSISAnimalsHumansEnteropathogenic Escherichia coliBiologyMolecular BiologyGene030304 developmental biologyEvolutionary BiologyScience & Technology030306 microbiologyANTIBIOTIC-RESISTANCESequence Analysis DNARC581-607biology.organism_classificationGenes BacterialImmunologic diseases. Allergy
researchProduct

COVID-19 Vaccine-Related Thrombosis: A Systematic Review and Exploratory Analysis

2021

IntroductionThe World Health Organization declared the coronavirus disease 2019 (COVID-19) pandemic on March 11, 2020. Two vaccine types were developed using two different technologies: viral vectors and mRNA. Thrombosis is one of the most severe and atypical adverse effects of vaccines. This study aimed to analyze published cases of thrombosis after COVID-19 vaccinations to identify patients’ features, potential pathophysiological mechanisms, timing of appearance of the adverse events, and other critical issues.Materials and MethodsWe performed a systematic electronic search of scientific articles regarding COVID-19 vaccine-related thrombosis and its complications on the PubMed (MEDLINE) d…

Settore BIO/17 - Istologiamedicine.medical_specialtyImmunologyMEDLINEvaccine-related thrombosisSettore MED/43 - Medicina LegalePF4 antibodiesInternal medicinePandemicmedicineCOVID 19 Vaccine Vaccine ThrombosisImmunology and AllergyPlateletAdverse effectvaccine complicationsbiologybusiness.industryvaccine adverse effectsRC581-607medicine.diseaseThrombosisPathophysiologyVaccinationbiology.proteinSystematic ReviewImmunologic diseases. AllergyAntibodybusinessCOVID-19 vaccineFrontiers in Immunology
researchProduct

Smoking, health and ageing.

2008

Abstract On March 19, 2008 a Symposium on Pathophysiology of Ageing and Age-Related diseases was held in Palermo, Italy. Here, the lecture of V. Nicita-Mauro on Smoking, health and ageing is summarized. Smoking represents an important ageing accelerator, both directly by triggering ana inflammatory responses, and indirectly by favoring the occurrence of several diseases where smoking is a recognized risk factor. Hence, non-smokers can delay the appearance of diseases and of ageing process, so attaining longevity.

Settore MED/04 - Patologia GeneraleGerontologylcsh:Immunologic diseases. AllergyAgingmedicine.medical_specialtyGeriatrics gerontologybusiness.industrymedia_common.quotation_subjectNicotine patchmedicine.medical_treatmentPublic healthImmunologyLongevityShort Reportlcsh:GeriatricsNicotine replacement therapyAgeinglcsh:RC952-954.6AgeingMedicineSmoking health ageingRisk factorbusinesslcsh:RC581-607media_commonImmunityageing : IA
researchProduct

Beliefs and preferences regarding biological treatments for severe asthma

2020

Background: Severe asthma is a serious condition with a significant burden on patients' morbidity, mortality, and quality of life. Some biological therapies targeting the IgE and interleukin-5 (IL5) mediated pathways are now available. Due to the lack of direct comparison studies, the choice of which medication to use varies. We aimed to explore the beliefs and practices in the use of biological therapies in severe asthma, hypothesizing that differences will occur depending on the prescribers’ specialty and experience. Methods: We conducted an online survey composed of 35 questions in English. The survey was circulated via the INterasma Scientific Network (INESNET) platform as well as throu…

Severe asthmaBehavior; Belief; Biological drug; Severe asthmainterleukine 5 IgEMULTICENTERDiseaseOmalizumabADD-ON THERAPYBehavior Belief Biological drug Severe asthmaDOUBLE-BLIND0302 clinical medicineMedicine and Health SciencesImmunology and AllergyEosinophil IL5 [Eos]030223 otorhinolaryngologyPulmonologistssevere asthma biological drug belief behavior3. Good healthBeliefSAFETYmedicine.druglcsh:Immunologic diseases. AllergyPulmonary and Respiratory Medicinemedicine.medical_specialtyEos: Eosinophil IL5ImmunologyBiological drugSpecialtylong-acting beta2-agonist OMASocio-culturaleSettore MED/10 - Malattie Dell'Apparato RespiratorioArticle03 medical and health sciencesQuality of life (healthcare)Omalizumab. OMA/IL5 Omalizumab plus anti-IL5 moleculeOMALIZUMABmedicineIntensive care medicineAsthmaBehaviorINterasma Scientific Network LABAbusiness.industryMEPOLIZUMABmedicine.diseaseEFFICACYICS inhaled corticosteroidsLIFE030228 respiratory systemImmunoglobulin E INESNETAllergistslcsh:RC581-607businessMepolizumab
researchProduct